胸腺五肽联合紫杉醇加顺铂化疗在晚期非小细胞肺癌治疗中的作用

Effect of the combined use of thymopentin and paclitaxel and cisplatin chemotherapy in the treatment of advanced non- small cell lung cancer

目的：评价胸腺五肽联合化疗对晚期非小细胞肺癌的效果。方法：64例晚期肺癌患者随机分为两组,观察组：TP方案加胸腺五肽。第1 d给予紫杉醇135 mg/m^2加5%葡萄糖注射液或0.9%生理盐水500 m L,静滴3 h;第1-3 d给予顺铂30 mg/m^2加0.9%生理盐水250 m L静滴;第1-14 d给予胸腺五肽1 mg加0.9%生理盐水250 m L静滴。对照组：单纯TP方案化疗,方法同上。3个化疗周期后观察患者近期疗效、血常规指标及不良反应情况。结果：两组近期疗效比较差异无统计学意义;化疗后观察组白细胞总数明显高于对照组,差异有统计学意义（P〈0.05）;化疗前后两组血红蛋白与血小板计数差异无统计学意义;观察组不良反应发生率明显低于对照组,差异有统计学意义（P〈0.05）。结论：胸腺五肽联合紫杉醇加顺铂化疗能提高晚期肺癌患者免疫功能,减少不良反应,提高生活质量,提高患者治疗依从性。

Objective： To observe the effect of the combined use of thymopentin and paclitaxel and cisplatin chemotherapy in the treatment of advanced non- small cell lung cancer（ NSCLC）. Methods： 64 patients with advanced NSCLC were randomized into two groups,the treatment group and the control group. The former received paclitaxel 135 mg / m2 in glucose injection（ 5 %） or normal saline（ 0. 9 %） 500 m L IV d1,cisplatin 30 mg / m2 in normal saline（ 0. 9 %） 250 m L IV d1 - d3,and thymopentin 1mg in normal saline（ 0. 9%） 250 m L IV d1 ~ d14. The latter was given the same therapy but thymopentin. The short- term effect,blood routine index and adverse reaction of all cases after 3 cycles of chemotherapy were observed. Results： There were no statistically significant differences in the short- term curative effect between the treatment group and the control group. Leukocyte count in the treatment group was higher than that in the control group after chemotherapy,with difference significant（ P 〈0. 05）. There was no difference in hemoglobin and blood platelet count between the two groups before and after chemotherapy. The incidence of adverse reaction in the treatment group was significantly lower than that in the control group（ P 〈0. 05）. Conclusion： The combined use of thymopentin and paclitaxel and cisplatin chemotherapy can increase the immunologic function of patients with advanced NSCLC,reducing the incidence rate of adverse effects,enhancing patients＇ quality of life and improving their treatment compliance.